159 related articles for article (PubMed ID: 36357185)
1. Predicting Cognitive Decline in Older Adults Using Baseline Metrics of AD Pathologies, Cerebrovascular Disease, and Neurodegeneration.
Prosser L; Macdougall A; Sudre CH; Manning EN; Malone IB; Walsh P; Goodkin O; Pemberton H; Barkhof F; Biessels GJ; Cash DM; Barnes J;
Neurology; 2023 Feb; 100(8):e834-e845. PubMed ID: 36357185
[TBL] [Abstract][Full Text] [Related]
2. White matter hyperintensities and CSF Alzheimer disease biomarkers in preclinical Alzheimer disease.
Soldan A; Pettigrew C; Zhu Y; Wang MC; Moghekar A; Gottesman RF; Singh B; Martinez O; Fletcher E; DeCarli C; Albert M;
Neurology; 2020 Mar; 94(9):e950-e960. PubMed ID: 31888969
[TBL] [Abstract][Full Text] [Related]
3. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.
Apostolova LG; Hwang KS; Kohannim O; Avila D; Elashoff D; Jack CR; Shaw L; Trojanowski JQ; Weiner MW; Thompson PM;
Neuroimage Clin; 2014; 4():461-72. PubMed ID: 24634832
[TBL] [Abstract][Full Text] [Related]
4. White matter hyperintensities and amyloid are independently associated with entorhinal cortex volume among individuals with mild cognitive impairment.
Guzman VA; Carmichael OT; Schwarz C; Tosto G; Zimmerman ME; Brickman AM;
Alzheimers Dement; 2013 Oct; 9(5 Suppl):S124-31. PubMed ID: 23375566
[TBL] [Abstract][Full Text] [Related]
5. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and
Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S
Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601
[TBL] [Abstract][Full Text] [Related]
6. Association of CSF GAP-43 With the Rate of Cognitive Decline and Progression to Dementia in Amyloid-Positive Individuals.
Öhrfelt A; Benedet AL; Ashton NJ; Kvartsberg H; Vandijck M; Weiner MW; Trojanowski JQ; Shaw LM; Zetterberg H; Blennow K;
Neurology; 2023 Jan; 100(3):e275-e285. PubMed ID: 36192174
[TBL] [Abstract][Full Text] [Related]
7. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
[TBL] [Abstract][Full Text] [Related]
8. Oh brother, where art tau? Amyloid, neurodegeneration, and cognitive decline without elevated tau.
McCollum LE; Das SR; Xie L; de Flores R; Wang J; Xie SX; Wisse LEM; Yushkevich PA; Wolk DA;
Neuroimage Clin; 2021; 31():102717. PubMed ID: 34119903
[TBL] [Abstract][Full Text] [Related]
9. Injury markers predict time to dementia in subjects with MCI and amyloid pathology.
van Rossum IA; Vos SJ; Burns L; Knol DL; Scheltens P; Soininen H; Wahlund LO; Hampel H; Tsolaki M; Minthon L; L'italien G; van der Flier WM; Teunissen CE; Blennow K; Barkhof F; Rueckert D; Wolz R; Verhey F; Visser PJ
Neurology; 2012 Oct; 79(17):1809-16. PubMed ID: 23019259
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal Relationships of White Matter Hyperintensities and Alzheimer Disease Biomarkers Across the Adult Life Span.
Luo J; Ma Y; Agboola FJ; Grant E; Morris JC; McDade E; Fagan AM; Benzinger TLS; Hassenstab J; Bateman RJ; Perrin RJ; Gordon BA; Goyal M; Strain JF; Yakushev I; Day GS; Xiong C;
Neurology; 2023 Jul; 101(2):e164-e177. PubMed ID: 37202169
[TBL] [Abstract][Full Text] [Related]
11. Age, vascular disease, and Alzheimer's disease pathologies in amyloid negative elderly adults.
Guo T; Landau SM; Jagust WJ;
Alzheimers Res Ther; 2021 Oct; 13(1):174. PubMed ID: 34654465
[TBL] [Abstract][Full Text] [Related]
12. Magnetic resonance imaging white matter hyperintensities and brain volume in the prediction of mild cognitive impairment and dementia.
Smith EE; Egorova S; Blacker D; Killiany RJ; Muzikansky A; Dickerson BC; Tanzi RE; Albert MS; Greenberg SM; Guttmann CR
Arch Neurol; 2008 Jan; 65(1):94-100. PubMed ID: 18195145
[TBL] [Abstract][Full Text] [Related]
13. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change.
Vemuri P; Wiste HJ; Weigand SD; Shaw LM; Trojanowski JQ; Weiner MW; Knopman DS; Petersen RC; Jack CR;
Neurology; 2009 Jul; 73(4):294-301. PubMed ID: 19636049
[TBL] [Abstract][Full Text] [Related]
14. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
[TBL] [Abstract][Full Text] [Related]
15. CSF p-tau/Aβ
Santangelo R; Masserini F; Agosta F; Sala A; Caminiti SP; Cecchetti G; Caso F; Martinelli V; Pinto P; Passerini G; Perani D; Magnani G; Filippi M
Eur J Nucl Med Mol Imaging; 2020 Dec; 47(13):3152-3164. PubMed ID: 32415550
[TBL] [Abstract][Full Text] [Related]
16. Prediction of fast decline in amyloid positive mild cognitive impairment patients using multimodal biomarkers.
Jang H; Park J; Woo S; Kim S; Kim HJ; Na DL; Lockhart SN; Kim Y; Kim KW; Cho SH; Kim SJ; Seong JK; Seo SW;
Neuroimage Clin; 2019; 24():101941. PubMed ID: 31376643
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease.
Zhang H; Therriault J; Kang MS; Ng KP; Pascoal TA; Rosa-Neto P; Gauthier S;
Alzheimers Res Ther; 2018 Aug; 10(1):80. PubMed ID: 30115118
[TBL] [Abstract][Full Text] [Related]
18. Biomarker-based prediction of progression in MCI: Comparison of AD signature and hippocampal volume with spinal fluid amyloid-β and tau.
Dickerson BC; Wolk DA;
Front Aging Neurosci; 2013; 5():55. PubMed ID: 24130528
[TBL] [Abstract][Full Text] [Related]
19. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.
Buchhave P; Minthon L; Zetterberg H; Wallin AK; Blennow K; Hansson O
Arch Gen Psychiatry; 2012 Jan; 69(1):98-106. PubMed ID: 22213792
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Diagnostic Performances Between Cerebrospinal Fluid Biomarkers and Amyloid PET in a Clinical Setting.
Jung NY; Kim ES; Kim HS; Jeon S; Lee MJ; Pak K; Lee JH; Lee YM; Lee K; Shin JH; Ko JK; Lee JM; Yoon JA; Hwang C; Choi KU; Lee EC; Seong JK; Huh GY; Kim DS; Kim EJ
J Alzheimers Dis; 2020; 74(2):473-490. PubMed ID: 32039853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
